Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19074158 | PLATELET DERIVATIVE COMPOSITIONS, AND PLURALITIES OF CONTAINERS CONTAINING SAME | March 2025 | April 2025 | Allow | 2 | 0 | 0 | No | No |
| 18850224 | PEPTIDE USEFUL FOR THE TRANSPORT OF MOLECULES THROUGH CELL BARRIERS | September 2024 | June 2025 | Allow | 9 | 1 | 0 | No | No |
| 18810381 | METHODS USING FREEZE-DRIED PLATELET DERIVATIVE COMPOSITIONS FOR RESTORING HEMOSTASIS IN A SUBJECT | August 2024 | February 2025 | Allow | 6 | 1 | 1 | Yes | No |
| 18770102 | PHOSPHO-TAU ANTIBODIES AND METHODS OF USE | July 2024 | March 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 18660156 | MODIFIED IMMUNOGLOBULINS FOR TARGETING AMYLOID DEPOSITS | May 2024 | July 2024 | Allow | 2 | 0 | 0 | No | No |
| 18660162 | MODIFIED IMMUNOGLOBULINS FOR TARGETING AMYLOID DEPOSITS | May 2024 | January 2025 | Allow | 9 | 2 | 0 | Yes | No |
| 18599751 | PHOSPHO-TAU ANTIBODIES AND METHODS OF USE | March 2024 | February 2025 | Allow | 11 | 1 | 0 | Yes | No |
| 18403419 | ANTIBODY SPECIFIC TO SPIKE PROTEIN OF SARS-COV-2 AND USES THEREOF | January 2024 | July 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18486053 | ANTI-IGE ANTIBODY THERAPY FOR MULTIPLE FOOD ALLERGIES | October 2023 | May 2024 | Allow | 7 | 1 | 1 | Yes | No |
| 18451751 | ANTIBODIES TO TICAGRELOR AND METHODS OF USE | August 2023 | April 2025 | Allow | 20 | 0 | 0 | No | No |
| 18450194 | THERAPEUTIC ANTIBODIES THAT BIND TO THE SERINE PROTEASE DOMAIN OF MASP-2 AND USES THEREOF | August 2023 | May 2024 | Allow | 9 | 2 | 1 | No | No |
| 18340722 | ANTI-FcRn ANTIBODY OR ANTIGEN BINDING FRAGMENT THEREOF WITH IMPROVED STABILITY | June 2023 | January 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18302033 | ANTI-COAGULATION FACTOR XI ANTIBODIES | April 2023 | December 2024 | Allow | 20 | 1 | 0 | Yes | No |
| 18134430 | EXCIPIENT COMPOUNDS FOR PROTEIN FORMULATIONS | April 2023 | December 2023 | Allow | 8 | 1 | 0 | Yes | No |
| 18182619 | TISSUE FACTOR PATHWAY INHIBITOR ANTIBODIES AND USES THEREOF | March 2023 | August 2024 | Allow | 17 | 0 | 0 | No | No |
| 18181489 | MODIFIED IMMUNOGLOBULINS FOR TARGETING AMYLOID DEPOSITS | March 2023 | March 2024 | Allow | 12 | 1 | 1 | Yes | No |
| 18171216 | ANTIBODIES CAPABLE OF BINDING TO THE SPIKE PROTEIN OF CORONAVIRUS SARS-COV-2 | February 2023 | February 2024 | Allow | 12 | 2 | 0 | Yes | No |
| 18151194 | Antigen Binding Molecules Targeting SARS-CoV-2 | January 2023 | February 2024 | Allow | 13 | 1 | 1 | No | No |
| 18087393 | SICKLED BETA GLOBIN ANTIBODIES | December 2022 | November 2024 | Allow | 22 | 1 | 0 | No | No |
| 18050240 | TISSUE FACTOR-TARGETED ANTIBODY-DRUG CONJUGATE | October 2022 | February 2025 | Allow | 27 | 2 | 1 | Yes | No |
| 18049559 | ANTI-BK VIRUS ANTIBODY MOLECULES | October 2022 | July 2023 | Allow | 9 | 1 | 0 | Yes | No |
| 17958759 | ANTI-TNF-ALPHA-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF | October 2022 | September 2024 | Allow | 23 | 1 | 0 | Yes | No |
| 17937744 | ANTIBODY SPECIFIC TO SPIKE PROTEIN OF SARS-COV-2 AND USES THEREOF | October 2022 | August 2023 | Allow | 11 | 1 | 1 | No | No |
| 17935134 | FUSION PROTEINS OF GDF15 AND USE THEREOF | September 2022 | November 2023 | Allow | 14 | 2 | 1 | Yes | No |
| 17952308 | MONOCLONAL ANTIBODY FOR SPIKE PROTEIN OF MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS, AND USE THEREOF | September 2022 | April 2024 | Allow | 19 | 1 | 0 | Yes | No |
| 17946917 | Methods For Prevention Of Graft Rejection In Xenotransplantation | September 2022 | January 2025 | Abandon | 28 | 3 | 1 | No | No |
| 17821937 | NEW BINDING AGENT AND ASSAY FOR PIVKA | August 2022 | March 2025 | Allow | 31 | 2 | 1 | Yes | No |
| 17890857 | ANTI-TNF-ALPHA-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF | August 2022 | March 2024 | Allow | 19 | 0 | 0 | No | No |
| 17819006 | DNASE FUSION POLYPEPTIDES AND RELATED COMPOSITIONS AND METHODS | August 2022 | July 2024 | Abandon | 24 | 1 | 1 | No | No |
| 17877853 | Anti-Tissue Factor Antibodies, Antibody-Drug Conjugates, and Related Methods | July 2022 | September 2024 | Allow | 26 | 0 | 1 | Yes | No |
| 17814075 | ANTIBODIES TO FELINE MCDONOUGH SARCOMA (FMS)-LIKE TYROSINE KINASE 3 RECEPTOR LIGAND (FLT3L) AND USES THEREOF FOR TREATING AUTOIMMUNE AND INFLAMMATORY DISEASES | July 2022 | September 2024 | Allow | 26 | 1 | 0 | Yes | No |
| 17838426 | ANTIBODIES TO LILRB2 | June 2022 | September 2024 | Abandon | 28 | 0 | 1 | No | No |
| 17711517 | TREATMENT OF ALLERGIC DISEASES WITH CHIMERIC PROTEIN | April 2022 | July 2024 | Allow | 27 | 1 | 1 | No | No |
| 17699460 | FACTOR VII (FVII(A))/TREM-LIKE TRANSCRIPT 1 (TLT-1) BISPECIFIC ANTIBODIES | March 2022 | July 2024 | Allow | 28 | 1 | 0 | No | No |
| 17655503 | HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) | March 2022 | September 2024 | Allow | 30 | 1 | 1 | No | No |
| 17681435 | METHODS OF REDUCING IMMUNOGENICITY AGAINST FACTOR VIII IN INDIVIDUALS UNDERGOING FACTOR VIII THERAPY | February 2022 | March 2025 | Allow | 37 | 2 | 1 | No | No |
| 17674438 | IgM-MEDIATED RECEPTOR CLUSTERING AND CELL MODULATION | February 2022 | September 2024 | Abandon | 31 | 0 | 1 | No | No |
| 17579517 | ANTI-PD-L1 ANTIBODY | January 2022 | February 2025 | Allow | 37 | 3 | 0 | Yes | No |
| 17627503 | FACTOR H POTENTIATING ANTIBODIES AND USES THEREOF | January 2022 | July 2023 | Allow | 18 | 1 | 0 | Yes | No |
| 17571075 | ANTIBODIES THAT RECOGNIZE RED BLOOD CELL ANTIGENS | January 2022 | February 2024 | Allow | 25 | 1 | 0 | No | No |
| 17541932 | ANTI-IgE ANTIBODIES | December 2021 | March 2024 | Allow | 28 | 1 | 0 | No | No |
| 17519719 | FACTOR VIII CHIMERIC PROTEINS AND USES THEREOF | November 2021 | January 2025 | Allow | 38 | 2 | 1 | No | Yes |
| 17498112 | METHOD OF TREATING ATHEROSCLEROSIS | October 2021 | September 2024 | Abandon | 35 | 1 | 1 | No | No |
| 17450423 | COAGULATION FACTOR BINDING PROTEINS AND USES THEREOF | October 2021 | October 2024 | Abandon | 36 | 0 | 1 | No | No |
| 17450122 | FACTOR XI ANTIBODIES AND METHODS OF USE | October 2021 | February 2024 | Allow | 28 | 1 | 1 | No | No |
| 16462878 | BISPECIFIC ANTIBODIES BINDING TO COAGULATION FACTOR IX AND COAGULATION FACTOR X | September 2021 | February 2025 | Allow | 60 | 1 | 1 | No | No |
| 17459395 | COMPOSITIONS AND METHODS FOR EVALUATING ANTICOAGULANT THERAPEUTIC EFFICACY | August 2021 | April 2025 | Allow | 43 | 1 | 0 | No | No |
| 17407040 | COMPOSITIONS FOR TREATING PATHOLOGICAL CALCIFICATION CONDITIONS, AND METHODS USING SAME | August 2021 | December 2023 | Abandon | 28 | 0 | 1 | No | No |
| 17378200 | METHODS OF USING FIX POLYPEPTIDES | July 2021 | October 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17355530 | ANTIBODIES TO COAGULATION FACTOR XIA AND USES THEREOF | June 2021 | January 2024 | Abandon | 31 | 0 | 1 | No | No |
| 17339021 | METHODS OF TREATING COMPLEMENT MEDIATED DISEASES WITH FUSION PROTEIN CONSTRUCTS COMPRISING ANTI-C3d ANTIBODY AND A COMPLEMENT MODULATOR | June 2021 | April 2023 | Allow | 22 | 0 | 1 | No | No |
| 17244159 | Method of Treating Asthma with a Complement C5 Inhibitor | April 2021 | December 2023 | Allow | 31 | 1 | 1 | Yes | No |
| 17239208 | CLOTTING FACTOR-FC CHIMERIC PROTEINS TO TREAT HEMOPHILIA | April 2021 | April 2024 | Abandon | 36 | 0 | 1 | No | No |
| 17235198 | COMBINATION THERAPY WITH COAGULATION FACTORS AND MULTISPECIFIC ANTIBODIES | April 2021 | March 2024 | Abandon | 35 | 0 | 1 | No | No |
| 17227029 | COMPOSITIONS CONTAINING ACTIVATABLE ANTIBODIES | April 2021 | June 2025 | Allow | 50 | 3 | 1 | Yes | No |
| 17282368 | BI-SPECIFIC BINDING AGENTS TARGETING SYNDECAN-1 AND FIBROBLAST GROWTH FACTOR RECEPTOR | April 2021 | November 2024 | Abandon | 44 | 0 | 1 | No | No |
| 17277572 | VACCINE AND ANTIBODY AGAINST CLOSTRIDIOIDES DIFFICILE TOXIN | March 2021 | August 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17198199 | HUMAN ANTIBODY DRUG CONJUGATES AGAINST TISSUE FACTOR | March 2021 | February 2024 | Abandon | 35 | 1 | 1 | No | No |
| 17274783 | METHODS FOR TREATING PANCREATITIS | March 2021 | March 2025 | Allow | 48 | 2 | 1 | No | No |
| 17196197 | ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | March 2021 | October 2024 | Abandon | 43 | 2 | 0 | No | No |
| 17196172 | PREPARATION OF FACTOR XA DERIVATIVES | March 2021 | August 2023 | Allow | 29 | 1 | 0 | No | No |
| 17271896 | Immunoconjugates Targeting EGFR | February 2021 | November 2024 | Abandon | 45 | 0 | 1 | No | No |
| 17176939 | INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR XA DERIVATIVES | February 2021 | May 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17166648 | METHODS OF TREATING ACQUIRED HEMOPHILIA WITH ANTI-FIBRINOLYTIC LOADED PLATELETS | February 2021 | February 2024 | Abandon | 37 | 1 | 0 | No | No |
| 17162982 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING LUPUS | January 2021 | January 2024 | Abandon | 35 | 1 | 0 | No | No |
| 17257705 | FX ACTIVATION PROCESS AND ITS USE IN THE PREPARATION OF A FXA COMPOSITION | January 2021 | December 2024 | Allow | 47 | 1 | 1 | Yes | No |
| 17137707 | Antibody-based blockage of SARS-CoV-2-specific furin cleavage site | December 2020 | April 2024 | Abandon | 39 | 1 | 1 | No | No |
| 17112280 | FACTOR VIII CHIMERIC AND HYBRID POLYPEPTIDES, AND METHODS OF USE THEREOF | December 2020 | August 2024 | Allow | 45 | 2 | 1 | No | Yes |
| 17096458 | ANTI-GPIIB/IIIA ANTIBODIES AND USES THEREOF | November 2020 | November 2023 | Abandon | 36 | 1 | 1 | No | No |
| 17092539 | ENDOSTATIN FRAGMENTS AND VARIANTS FOR USE IN TREATING FIBROSIS | November 2020 | October 2023 | Allow | 35 | 3 | 1 | No | No |
| 17085128 | IMMUNOGLOBULINS AND USES THEREOF | October 2020 | June 2024 | Allow | 44 | 1 | 1 | No | No |
| 17076042 | COMPLEMENT FACTOR H ANTIBODIES | October 2020 | May 2024 | Abandon | 42 | 3 | 0 | Yes | No |
| 17046395 | ANTI-COMPLEMENT COMPONENT ANTIBODIES AND METHODS OF USE | October 2020 | November 2023 | Abandon | 37 | 1 | 1 | No | No |
| 17063905 | FIXaxFX Bispecific Antibody with Common Light Chain | October 2020 | June 2023 | Allow | 32 | 1 | 0 | No | No |
| 17041291 | METHODS OF TREATING CHRONIC SPONTANEOUS URTICARIA USING LIGELIZUMAB | September 2020 | December 2023 | Abandon | 39 | 2 | 0 | No | Yes |
| 16995173 | LYOPHILIZED FACTOR IX FORMULATIONS | August 2020 | June 2024 | Allow | 46 | 2 | 0 | Yes | Yes |
| 16994573 | MODIFIED FACTOR VII POLYPEPTIDES FOR SUBCUTANEOUS ADMINISTRATION AND ON-DEMAND TREATMENT | August 2020 | August 2024 | Abandon | 48 | 2 | 1 | No | No |
| 16993979 | FACTOR VIII POLYPEPTIDE FORMULATIONS | August 2020 | April 2025 | Allow | 56 | 3 | 1 | Yes | Yes |
| 16969788 | NOVEL HUMANIZED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR, ITS NUCLEIC ACID SEQUENCE AND ITS PREPARATION | August 2020 | February 2025 | Allow | 54 | 1 | 1 | Yes | No |
| 16967514 | METHODS OF TREATING INITIAL EPISODE OF TTP WITH IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS | August 2020 | January 2024 | Allow | 42 | 3 | 1 | No | No |
| 16967294 | ISOLATED CHIMERIC ANTIGEN RECEPTOR, MODIFIED T CELL COMPRISING SAME AND USE THEREOF | August 2020 | June 2024 | Abandon | 46 | 0 | 1 | No | No |
| 16959652 | Anti-Tissue Factor Antibodies, Antibody-Drug Conjugates, and Related Methods | July 2020 | August 2024 | Abandon | 49 | 3 | 1 | Yes | No |
| 16907985 | FACTOR IX POLYPEPTIDES AND METHODS OF USE THEREOF | June 2020 | October 2023 | Abandon | 39 | 1 | 0 | No | No |
| 16771700 | METHODS FOR PREPARING AND USING HIGHLY ACTIVE BLOOD COAGULATION FACTOR XI MUTANT AND GENE THERAPY/EDITING VECTOR AND RECOMBINANT/FUSION PROTEIN THEREOF | June 2020 | December 2023 | Allow | 42 | 1 | 0 | Yes | No |
| 16881911 | EVALUATION, ASSAYS AND TREATMENT OF PKAL-MEDIATED DISORDERS | May 2020 | September 2023 | Allow | 40 | 2 | 1 | No | No |
| 16766327 | COMPOSITIONS FOR INTERFERON BLOCKADE AND METHODS OF USING SAME | May 2020 | March 2024 | Allow | 45 | 3 | 1 | No | No |
| 16763524 | FORCE SENSOR CLEAVAGE DOMAIN CONTAINING CHIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF | May 2020 | April 2024 | Allow | 47 | 1 | 1 | No | No |
| 16869117 | ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | May 2020 | July 2023 | Allow | 39 | 1 | 1 | No | No |
| 16761769 | METHOD FOR DETERMINING FACTOR XA INHIBITOR DOSAGE | May 2020 | November 2023 | Allow | 42 | 2 | 1 | No | No |
| 16644355 | AQUEOUS PHARMACEUTICAL COMPOSITION | March 2020 | November 2023 | Allow | 44 | 2 | 1 | No | No |
| 16643942 | DELIVERY OF PAYLOADS TO STEM CELLS | March 2020 | February 2025 | Abandon | 60 | 3 | 1 | No | No |
| 16630768 | RAPID ELICITATION OF BROADLY NEUTRALIZING ANTIBODIES TO HIV ENV | January 2020 | June 2023 | Allow | 41 | 2 | 1 | No | No |
| 16726411 | STRATEGIES TO PREVENT AND/OR TREAT IMMUNE RESPONSES TO SOLUBLE ALLOFACTORS | December 2019 | February 2024 | Abandon | 50 | 2 | 1 | No | No |
| 16625109 | BISPECIFIC ANTIBODIES FOR FACTOR IX AND FACTOR X | December 2019 | June 2023 | Allow | 42 | 2 | 1 | No | Yes |
| 16622064 | Binding Molecule Activating FXII | December 2019 | August 2023 | Allow | 44 | 2 | 1 | No | No |
| 16617846 | POLYPEPTIDES BINDING ADAMTS5, MMP13 AND AGGRECAN | November 2019 | July 2023 | Allow | 43 | 4 | 1 | No | No |
| 16612476 | GLYCOSYLATION OF VARIABLE IMMUNOGLOBULIN DOMAINS | November 2019 | September 2023 | Allow | 46 | 3 | 1 | No | No |
| 16666886 | THERAPY USING A FACTOR XII INHIBITOR IN A NEUROTRAUMATIC DISORDER | October 2019 | April 2024 | Allow | 53 | 3 | 1 | No | No |
| 16494177 | METHODS AND COMPOSITIONS RELATED TO A TISSUE FACTOR-TARGETING IGG3 IMMUNOCONJUGATES | September 2019 | August 2023 | Allow | 47 | 2 | 1 | Yes | No |
| 16537427 | ANTI-COAGULATION FACTOR XI ANTIBODY | August 2019 | December 2023 | Allow | 52 | 4 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SZPERKA, MICHAEL EDWARD.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 41.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner SZPERKA, MICHAEL EDWARD works in Art Unit 1641 and has examined 264 patent applications in our dataset. With an allowance rate of 86.7%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 34 months.
Examiner SZPERKA, MICHAEL EDWARD's allowance rate of 86.7% places them in the 60% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by SZPERKA, MICHAEL EDWARD receive 1.92 office actions before reaching final disposition. This places the examiner in the 61% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by SZPERKA, MICHAEL EDWARD is 34 months. This places the examiner in the 22% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +18.9% benefit to allowance rate for applications examined by SZPERKA, MICHAEL EDWARD. This interview benefit is in the 65% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 30.5% of applications are subsequently allowed. This success rate is in the 52% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 62.5% of cases where such amendments are filed. This entry rate is in the 84% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 68% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 95.8% of appeals filed. This is in the 84% percentile among all examiners. Of these withdrawals, 91.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 37.0% are granted (fully or in part). This grant rate is in the 33% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 8.0% of allowed cases (in the 94% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 6.1% of allowed cases (in the 82% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.